海外の治験の状況「COVID-19」での検索結果
1件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A global study to assess the effects of osimertinib following chemoradiation in patients with Stage III unresectable non-small cell lung cancer (LAURA).
- Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation. MedDRA version: 20.0 Level: PT Classification code 10029519 Term: Non-small cell lung cancer stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, China, India, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United States, Vietnam
- 2018-06-21
- 1
